Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiology Groups Stress Year-Long Antiplatelet Therapy For Stent Patients

Executive Summary

"Strong" consideration should be given to avoiding drug-eluting stents in patients who are not expected to continue dual antiplatelet therapy for a full 12 months, according to a 1science advisory posted online by leading medical organizations

You may also be interested in...

Stent worries may help Plavix

FDA's Circulatory System Devices Panel recommends extended use of Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) for reducing risk of thrombosis associated with drug-eluting stents. During its Dec. 7-8 meeting, the panel suggested FDA align DES labeling with American Heart Association guidelines that the antiplatelet therapy be taken for up to a year if a patient does not exhibit excessive bleeding. An observational study published in the Dec. 5 Journal of the American Medical Association found better outcomes were achieved the longer patients took Plavix, up to one year. FDA is considering changing DES labeling to reflect the need for anticlotting regimens that last longer than the three months recommended for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent and the six months recommended for Boston Scientific's Taxus paclitaxel-eluting stent...

Study Shows No Death, MI Advantages For Stenting Over Medical Therapy

Results form the 2,287-patient COURAGE trial presented the American College of Cardiology meeting should give physicians more to think about before moving forward with percutaneous coronary intervention in stable heart disease patients, researchers say.

FDA Aims To Up Transparency By Making Panel Materials Public Sooner

FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts